Loading patent…
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsAnders H. Berg, S. Ananth Karumanchi, Ravi I. Thadhani
Estimating the term…
The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.
A method for diagnosing kidney disease, determining the likelihood of developing kidney disease, or determining the severity of kidney disease in a subject, said method comprising determining the fraction of carbamylated albumin in said subject, wherein an increased fraction of carbamylation of said albumin, as compared to a control, is indicative of the presence of disease, an increased likelihood of developing disease, or increased disease severity.
(canceled)
(canceled)
A method comprising determining the fraction of carbamylated albumin in a subject, wherein said subject has or is suspected of having kidney disease.
(canceled)
(canceled)
A method of treating or treating prophylactically a subject having kidney disease or a method of reducing protein carbamylation in a subject, said method comprising administering to said subject an effective amount of a composition capable of being carbamylated.
(canceled)
An antibody or antibody fragment that specifically binds albumin carbamylated at lysine 549, but does not bind uncarbamylated albumin.
Dependencies are inferred from the claim text.